ANI Pharmaceuticals added a new face to its board on August 19: Henry Gosebruch, who will serve through the 2027 annual shareholder meeting. The 53-year-old brings serious credentials — about seven years as AbbVie's EVP and Chief Strategy Officer, a stint as CEO of neuroscience company Neumora Therapeutics, his current role as CEO of Lakefront Biotherapeutics, and over two decades at J.P. Morgan where he co-headed North American M&A. Per the company's standard non-employee director package, he'll receive an initial restricted stock award worth $525,000, vesting in equal installments over three years. Separately, director Samy Shanmugam resigned from the board effective August 23, though he stays on in his day job as ANI's Head of Research & Development and COO of New Jersey Operations.
View Full Filing (SEC EDGAR)